Paul Zachary Lamberty: Final Debarment Order
Published Date: 2/6/2026
Notice
Summary
Paul Zachary Lamberty is officially banned for 10 years from importing any drugs into the U.S. because he was convicted of serious crimes involving fake and misleading drugs. He didn’t respond to the FDA’s chance to defend himself, so the ban starts on February 6, 2026. If he wants to end the ban early, he can apply anytime but must be careful about sharing private info.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
10-Year Import Ban for Lamberty
Paul Zachary Lamberty is banned for 10 years from importing or offering for import any drug into the United States. The debarment is effective February 6, 2026 and is based on his May 30, 2025 federal felony convictions for conspiracy and introduction of misbranded drugs with intent to defraud and mislead.
Importing With Lamberty Is Prohibited
Importing or offering for import any drug into the United States by, with the assistance of, or at the direction of Paul Zachary Lamberty is a prohibited act under section 301(cc) of the FD&C Act. This prohibition is effective February 6, 2026.
Termination Application & Confidentiality Rules
Mr. Lamberty may apply at any time to ask for early termination of the debarment under section 306(d)(1) of the FD&C Act. Applications submitted electronically will be posted publicly, so confidential information must be submitted as a written/paper submission following the FDA instructions to protect confidential material.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-02336 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of Currently Approved Collection: Title-Campus Program Grantee Needs and Progress Assessment Tool
The Department of Justice’s Office on Violence Against Women is asking for more time to keep using a survey tool that helps campus program grantees track their needs and progress. They want your feedback on how this tool works and how to make it easier to use. If you’re involved in these programs, you can share your thoughts by April 7, 2026—no extra costs, just a chance to improve the process!
Next: 2026-02339 — Codex Alimentarius Commission: Meeting of the Codex Committee on Methods of Analysis and Sampling
The U.S. Codex Office is hosting a public video meeting on February 19, 2026, to share info and gather feedback on food testing and sampling rules before the big Codex meeting in Hungary in March. This affects food producers, labs, and anyone interested in food safety standards. Joining the meeting and submitting comments helps shape U.S. positions, with no costs but important deadlines to keep in mind.